EUVIMEDEUVIMED entdecken
Crossref

Real-world evaluation of [177Lu]Lu-PSMA-617 RLT in post-taxane mCRPC: feasibility and safety of individualized treatment in a challenging cohort

Muammer Misirci, Florian Rosar, Fadi Khreish, Caroline Burgard, Arne Blickle, Mark Bartholomä, Stephan Maus, Moritz B Bastian, Tilman Speicher, Sven Petto, Sebastian Ganz, Andrea Schaefer-Schuler und 1 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2026

DOI: 10.1007/s00259-026-08037-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Muammer Misirci und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Saarland University - Medical Center, Kirrberger Str. 100, Geb. 50, Homburg, D-66421, Germany. Hauptthemen laut MEDLINE: Dipeptides, Heterocyclic Compounds, 1-Ring, Prostatic Neoplasms, Castration-Resistant, Lutetium. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DipeptidesHeterocyclic Compounds, 1-RingProstatic Neoplasms, Castration-ResistantLutetiumBridged-Ring CompoundsPrecision MedicineSafetyHumansMaleAgedFeasibility StudiesMiddle AgedAged, 80 and overRadioisotopesTreatment OutcomeCohort StudiesProstate-Specific AntigenTaxoids

Stichwörter der Autor:innen

177Lu-PSMAOutcome predictorsPSMA radioligand therapyPost-taxane mCRPCReal-world analysis

Substanzen

DipeptidesHeterocyclic Compounds, 1-RingLutetiumBridged-Ring CompoundstaxaneLutetium-177RadioisotopesPSMA-617Prostate-Specific AntigenTaxoids

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Saarland University - Medical Center, Kirrberger Str. 100, Geb. 50, Homburg, D-66421, Germany.
  • Department of Nuclear Medicine, Marburg University - Campus Fulda, Fulda, Germany.
  • Department of Nuclear Medicine, Saarland University - Medical Center, Kirrberger Str. 100, Geb. 50, Homburg, D-66421, Germany. samer.ezziddin@uks.eu.

Zitieren

APA

Misirci, M., Rosar, F., Khreish, F., Burgard, C., Blickle, A., Bartholomä, M., Maus, S., Bastian, M. B., Speicher, T., Petto, S., Ganz, S., Schaefer-Schuler, A., & Ezziddin, S. (2026). Real-world evaluation of [177Lu]Lu-PSMA-617 RLT in post-taxane mCRPC: feasibility and safety of individualized treatment in a challenging cohort. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08037-4

Vancouver

Misirci M, Rosar F, Khreish F, Burgard C, Blickle A, Bartholomä M, et al. Real-world evaluation of [177Lu]Lu-PSMA-617 RLT in post-taxane mCRPC: feasibility and safety of individualized treatment in a challenging cohort. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-026-08037-4

BibTeX
@article{Misirci2026,
  author = {Misirci, Muammer and Rosar, Florian and Khreish, Fadi and Burgard, Caroline and Blickle, Arne and Bartholomä, Mark and Maus, Stephan and Bastian, Moritz B and Speicher, Tilman and Petto, Sven and Ganz, Sebastian and Schaefer-Schuler, Andrea and Ezziddin, Samer},
  title = {Real-world evaluation of [177Lu]Lu-PSMA-617 RLT in post-taxane mCRPC: feasibility and safety of individualized treatment in a challenging cohort},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  doi = {10.1007/s00259-026-08037-4}
}
Kostenlos starten →